Literature DB >> 25023622

Animal models for viral infection and cell exhaustion.

Colleen S McGary1, Guido Silvestri, Mirko Paiardini.   

Abstract

PURPOSE OF REVIEW: Despite eliciting an early antiviral T cell response, HIV-specific T cells are unable to prevent disease progression, partly because of their loss of effector functions, known as T cell exhaustion. Restoring this T cell functionality represents a critical step for regaining immunological control of HIV-1 replication, and may be fundamental for the development of a functional cure for HIV. In this context, the use of animal models is invaluable for evaluating the efficacy and mechanisms of novel therapeutics aimed at reinvigorating T cell functions. RECENT
FINDINGS: Although nonhuman primates continue to be a mainstay for studying HIV pathogenesis and therapies, recent advances in humanized mouse models have improved their ability to recapitulate the features of cell exhaustion during HIV infection. Targeting coinhibitory receptors in HIV-infected and simian immunodeficiency virus (SIV)-infected animals has resulted in viral load reductions, presumably by reinvigorating the effector functions of T cells. Additionally, studies combining programmed death-1 (PD-1) blockade with suppressive antiretroviral therapy provide further support to the use of coinhibitory receptor blockades in restoring T cell function by delaying viral load rebound upon antiretroviral therapy interruption. Future in-vivo studies should build on recent in-vitro data, supporting the simultaneous targeting of multiple regulators of cell exhaustion.
SUMMARY: In this review, we describe the most recent advances in the use of animal models for the study of cell exhaustion following HIV/SIV infection. These findings suggest that the use of animal models is increasingly critical in translating immunotherapeutics into clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25023622      PMCID: PMC4180228          DOI: 10.1097/COH.0000000000000093

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  71 in total

1.  p38 Mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells.

Authors:  Karlhans Fru Che; Esaki Muthu Shankar; Sundaram Muthu; Sasan Zandi; Mikael Sigvardsson; Jorma Hinkula; Davorka Messmer; Marie Larsson
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

2.  Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.

Authors:  Filippos Porichis; Meghan G Hart; Jennifer Zupkosky; Lucie Barblu; Douglas S Kwon; Ashley McMullen; Thomas Brennan; Rafi Ahmed; Gordon J Freeman; Daniel G Kavanagh; Daniel E Kaufmann
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

3.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

4.  In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice.

Authors:  Brent E Palmer; C Preston Neff; Jonathan Lecureux; Angelica Ehler; Michelle Dsouza; Leila Remling-Mulder; Alan J Korman; Andrew P Fontenot; Ramesh Akkina
Journal:  J Immunol       Date:  2012-12-03       Impact factor: 5.422

5.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

6.  In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit.

Authors:  Praveen K Amancha; Jung Joo Hong; Kenneth Rogers; Aftab A Ansari; Francois Villinger
Journal:  J Immunol       Date:  2013-11-13       Impact factor: 5.422

7.  Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads.

Authors:  Kirsten K Dietze; Gennadiy Zelinskyy; Jia Liu; Freya Kretzmer; Simone Schimmer; Ulf Dittmer
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

8.  PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.

Authors:  Edward Seung; Timothy E Dudek; Todd M Allen; Gordon J Freeman; Andrew D Luster; Andrew M Tager
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

Review 9.  Molecular signatures of T-cell inhibition in HIV-1 infection.

Authors:  Marie Larsson; Esaki M Shankar; Karlhans F Che; Alireza Saeidi; Rada Ellegård; Muttiah Barathan; Vijayakumar Velu; Adeeba Kamarulzaman
Journal:  Retrovirology       Date:  2013-03-20       Impact factor: 4.602

10.  Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection.

Authors:  Jung Joo Hong; Praveen K Amancha; Kenneth Rogers; Aftab A Ansari; Francois Villinger
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more
  4 in total

Review 1.  The Contributions of Clinical Pharmacology to HIV Cure Research.

Authors:  Courtney V Fletcher; Shetty Ravi Dyavar; Arpan Acharya; Siddappa N Byrareddy
Journal:  Clin Pharmacol Ther       Date:  2021-04-18       Impact factor: 6.903

Review 2.  Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.

Authors:  Isobel S Okoye; Michael Houghton; Lorne Tyrrell; Khaled Barakat; Shokrollah Elahi
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

Review 3.  The Roles of Coinhibitory Receptors in Pathogenesis of Human Retroviral Infections.

Authors:  Keiko Yasuma-Mitobe; Masao Matsuoka
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

4.  PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia.

Authors:  Cristina Peligero; Jordi Argilaguet; Roberto Güerri-Fernandez; Berta Torres; Carmen Ligero; Pilar Colomer; Montserrat Plana; Hernando Knobel; Felipe García; Andreas Meyerhans
Journal:  PLoS Pathog       Date:  2015-12-03       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.